Fig. 1
From: B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
TIM-1 blockade in B cells enhances the sensing of IFN by B cells. This leads to an augmented IFN-I response, increased B cell activation, enhanced antigen presentation, and improved co-stimulation. Consequently, there is an increase in inflammatory cytokine production and responsiveness, resulting in enhanced effector T cell responses. Created with BioRender.com
